OptimizeRx(OPRX) - 2025 Q1 - Quarterly Results

Revenue Performance - Q1 2025 revenue reached $21.9 million, an 11% increase year-over-year from $19.7 million in Q1 2024[1] - Full-year 2025 revenue guidance raised to a range of $101 million to $106 million, with adjusted EBITDA expected between $13 million and $15 million[1][7] - Year-to-date contracted revenue is up more than 20% compared to the same period last year, indicating strong momentum[3] - Net revenue for Q1 2025 was $21,928 million, a 11.5% increase from $19,690 million in Q1 2024[24] Profitability - Q1 2025 gross profit increased by 9% year-over-year to $13.3 million, up from $12.2 million in Q1 2024[5] - Non-GAAP net income for Q1 2025 was $1.5 million, or $0.08 per diluted share, compared to a non-GAAP net loss of $(2.0) million, or $(0.11) per diluted share in Q1 2024[5] - Adjusted EBITDA for Q1 2025 increased to $1.5 million, compared to $(0.3) million in the same year-ago period[5] - Net loss for Q1 2025 decreased to $2,199 million from $6,899 million in Q1 2024, representing a 68.1% improvement[24] - Non-GAAP net income for Q1 2025 was $1,539 million, compared to a loss of $1,964 million in Q1 2024[29] - Adjusted EBITDA for Q1 2025 was $1,489 million, a significant improvement from a loss of $276 million in Q1 2024[30] Cash and Liquidity - Cash and cash equivalents totaled $16.6 million as of March 31, 2025, up from $13.4 million as of December 31, 2024[5] - Cash provided by operating activities for Q1 2025 was $3,864 million, an increase from $2,118 million in Q1 2024[26] - Cash and cash equivalents at the end of Q1 2025 were $16,573 million, up from $15,177 million at the end of Q1 2024[26] Customer Metrics - Over 5% of expected 2025 sales have been converted into subscription-based revenue streams, enhancing revenue stability[4] - Average revenue per top 20 pharmaceutical manufacturer increased to $2,960, up from $2,592 in 2024[6] - Net revenue retention stood at 114% for the twelve months ended March 31, 2025, compared to 116% in 2024[6] Operating Expenses - Operating expenses for Q1 2025 totaled $15,458 million, down from $17,233 million in Q1 2024, a reduction of 10.3%[24] Shareholder Metrics - Weighted average shares outstanding for diluted earnings in Q1 2025 were 18,579,012, compared to 18,170,108 in Q1 2024[29] - Loss per share for Q1 2025 was $0.12, an improvement from $0.38 in Q1 2024[24]